Drug Trial Radar · NCT06898047
Consistency of Response With Rimegepant in Acute Treatment of Migraine
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Nov 15, 2025
Primary completion
Oct 24, 2026
Study completion Oct 24, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 27, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.
Conditions
- Migraine
Interventions
Rimegepant for acute migraine treatmentDrug
Rimegepant for acute migraine treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Meaninful Pain Relief (MPR) post-dosingTime frame: Daily (within 24hs post dose)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.